JBT Marel
Valuation each multiple against its own 5-year range
Vs. peers Specialty Industrial Machinery
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| JBT Marel (JBTM) | 6.15B | 32.13 | 1.39 | 0.33% |
| GE Vernova (GEV) | 185.10B | 18.36 | 16.26 | 0.25% |
| Eaton (ETN) | 120.95B | 31.01 | 5.77 | 1.39% |
| Parker Hannifin (PH) | 109.94B | 29.95 | 6.88 | 0.87% |
| Emerson Electric (EMR) | 82.80B | 31.51 | 3.99 | 1.47% |
| Illinois Tool Works (ITW) | 77.75B | 24.40 | 24.75 | 2.39% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 29.3% below Morningstar's fair value estimate.
Fair value
JBT Marel Corp is assigned a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 19% discount to our quantitative fair value estimate of $155.85 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.
The firm's solid growth increases our estimated valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 33.6% lies in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are cheap.
Conversely, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's price to cash ratio of 66.9, for example, falls in the top 10% globally. The company's available liquid assets are low relative to the stock's market value. Depending on the absolute cash balance, the company could also face a liquidity shortage if economic circumstances take a turn for the worse. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
JBT Marel discussion 0 comments